Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 26 September 2016 | By Zachary Brennan
The new collaboration between the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) announced Monday will improve the sharing of information on various aspects of the development and scientific evaluation of medicines for rare diseases.
According to EMA, rare diseases affect 30 million people in the EU and approximately the same number in the US, though each disease individually concerns a limited number of patients. And since only a limited number of studies can be conducted for such small populations, both regulators are calling for more global collaboration.
The collaboration, known in the EU as a cluster, will focus on:
Both regulators will allow for the confidential exchange of draft documents, policies under development and the discussion of more detailed information supporting the scientific basis for decision making.
The first meeting of the rare diseases cluster took place by teleconference on 23 September and future teleconferences will occur monthly, subject to need and predefined in advance, for approximately one hour and 30 minutes.
EMA also clarified that the existing EMA/FDA “cluster on orphan medicinal products” will continue to focus on information sharing and collaboration on orphan designation and exclusivity, as well as the agencies’ mechanisms to encourage the development of medicines for rare diseases.
Other currently existing EMA/FDA clusters discuss issues related to patient engagement, biosimilars, orphan medicines, cancer treatments, pediatric medicines and pharmacovigilance.
Terms of reference for the EMA/FDA cluster on rare diseases
Tags: rare disease, FDA and EMA collaboration, rare disease cluster